Rimantadine 50 mg (20 tablets)

The instruction for medical use of medicine Rimantadinum the Trade name Rimantadinum International Unlicensed Name Rimantadinum Dosage Form of the Tablet, 50 mg Structure One tablet contains active agent – Rimantadinum a hydrochloride of 50.0 mg, excipients: lactoses monohydrate, potato starch, calcium (magnesium) stearate. The description of the Tablet of white color, round shape, with a flat surface, with a facet. Pharmacotherapeutic group Antiviral drugs for system use. Antiviral drugs of direct action. Cyclic amines. Rimantadinum the ATX J05AC02 Code the Pharmacological Pharmacokinetics Later properties of intake Rimantadinum is almost completely soaked up in intestines. Absorption is slow. TCmax - 1-4 h. Communication with proteins of plasma - about 40%. Concentration in a nasal secret is 50% higher, than plasma. The size Cmax at reception of 100 mg of 1 times a day - 181 ng/ml, on 100 mg 2 times a day - 416 ng/ml. It is metabolized in a liver. Plasma elimination half-life of blood makes 24-36 h, more than 90% are removed by kidneys during 72 h, generally in the form of metabolites, 15% - in not changed look. In a renal failure the elimination half-life increases twice. At persons with a renal failure and at elderly people can collect in toxic concentration if the dose is not adjusted in proportion to reduction of clearance of creatinine. A pharmacodynamics Rimantadinum - the antiviral means derivative of an adamantan, is effective concerning various influenza strains And, viruses of tick-borne encephalitis. Has anti-toxic and immunomodulatory effect. The polymeric structure provides long circulation of Rimantadinum in an organism that allows to apply it not only with medical, but also with the preventive purpose. Suppresses an early stage of a specific reproduction (after penetration of a virus into a cell and to an initial transcription of RNA), an exit of virus particles from a cell oppresses, i.e. interrupts a transcription of a virus genome, the alpha and scale induces development of interferon, increases functional lymphocyte activity - natural killers (NK cells), T- and B-lymphocytes. Indications - early treatment and prevention of flu at adults and children are more senior than 7 years - prevention of flu in the period of epidemics at adults the Route of administration and doses accept Rimantadinum inside after a meal, washing down with water. Use of drug needs to be begun right after emergence of the first symptoms of flu. The therapeutic effect is more significant if use is begun within the first 48 hours of a disease. Treatment of flu by the Adult and to children is 15 years and 300 mg/days (6 tablets) for 2-3 receptions, in the 2nd and 3rd days of 100 mg (2 tablets) 2 times a day, in the 4th and 5th days of 100 mg (2 tablets) of 1 times a day are more senior in the 1st day. Children are 7-10 years old on 1 tablet 2 times a day, 11–14 years — 1 tablet 3 times a day. Duration of a course of treatment is 5 days. Prevention of flu: the adult on 1 tablet once a day lasting 10-15 days. Side effects - a headache, dizziness, insomnia, alarm, disturbance of concentration of attention, a tremor, excessive fatigue, an ataxy, hyperexcitability, a depression, euphoria, a hyperkinesia - dryness in a mouth, anorexia, nausea, vomiting, gastralgias, a meteorism - a hyperbilirubinemia - allergic reactions (rash, an itching, urticaria) it is possible - exacerbation of chronic associated diseases (during treatment) - development of a hemorrhagic stroke (at patients of advanced age with arterial hypertension) - pallor of integuments, tachycardia - short wind, cough, a bronchospasm - a ring in ears, change of taste and sense of smell of the Contraindication - hypersensitivity to derivatives of group of an adamantan and auxiliary components of drug - an acute liver failure - a renal failure - a thyrotoxicosis - pregnancy, the lactation period - children's age up to 7 years With care - arterial hypertension - epilepsy (including. in the anamnesis) - atherosclerosis of vessels of a brain Medicinal interactions Paracetamol and acetylsalicylic acid reduce concentration of Rimantadinum in blood plasma and reduce its efficiency. Cimetidinum reduces clearance of Rimantadinum by 18%. Rimantadinum reduces efficiency of antiepileptic drugs. The adsorbents knitting and enveloping means reduce Rimantadinum absorption. Special instructions patients Should be careful when assigning with digestive tract diseases, disturbances of functions of a liver, a serious illness of heart and disturbances of a warm rhythm. In these cases it is recommended to lower a drug dose. During treatment by Rimantadinum it is necessary to refuse intake of alcoholic beverages. At instructions in the anamnesis on epilepsy and the carried-out anticonvulsant therapy against the background of Rimantadin's use the risk of developing an epileptic seizure increases. In these cases the dose of drug is reduced to 100 mg (2 tablets) a day. If the attack develops, intake of Rimantadinum is stopped. Features of influence of medicine on ability to run the vehicle or potentially dangerous mechanisms Rimantadinum does not affect ability to run the vehicle or potentially dangerous mechanisms, but to persons at whom arise dizziness a headache or other side effects from the central nervous system, it is necessary to be careful. Overdose Symptoms: excitement, hallucinations, arrhythmia. Treatment: in poisoning it is necessary to support life-supporting functions. At overdose with symptoms from the central nervous system effectively intravenous administration of physostigmine. Rimantadinum is partially removed by a hemodialysis. A form of release and packing On 10 tablets in planimetric bezjyacheykovy packing from paper packing with a polymeric covering from two parties or on 20 tablets in banks from polyethylene. On 250 planimetric packs or on 20 cans together with iinstruktion on medical use in the state and Russian languages place in a cardboard box (group packing). To Store storage conditions in the dry, protected from light place, at a temperature not above 25 °C. To store out of children's reach! A period of storage 2 years not to apply after an expiration date Prescription status Without prescription Eykos-Pharm LLP Producer, the Republic of Kazakhstan, Almaty region, Karasaysky district, the Eltaysky rural district, the station 71 travel. The owner of the registration certificate of Eykos-Pharm LLP, Kazakhstan the Name, the address and a contact information of the organization which is in the territory of the Republic of Kazakhstan and accepting claims on quality of medicines from consumers and responsible for post-registration observation of safety of medicine: Eykos-Pharm LLP Address of office: Almaty, Nusupbekov St., 32 ph. + 7 (727) 397 64 29, + 7 (727) 329 66 07 fax: + 7 (727) 250 71 78, e-mail: pharm@eikos.kz